These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 28432657)
1. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization. Gilabert-Oriol R; Chernov L; Anantha M; Dragowska WH; Bally MB Drug Deliv Transl Res; 2017 Aug; 7(4):544-557. PubMed ID: 28432657 [TBL] [Abstract][Full Text] [Related]
2. Optimization of liposomal topotecan for use in treating neuroblastoma. Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814 [TBL] [Abstract][Full Text] [Related]
3. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060 [TBL] [Abstract][Full Text] [Related]
4. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity. Li C; Wang C; Yang H; Zhao X; Wei N; Cui J J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269 [TBL] [Abstract][Full Text] [Related]
5. The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan. Fugit KD; Anderson BD J Control Release; 2014 Jan; 174():88-97. PubMed ID: 24231406 [TBL] [Abstract][Full Text] [Related]
6. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767 [TBL] [Abstract][Full Text] [Related]
7. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer. Jain A; Jain SK Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330 [TBL] [Abstract][Full Text] [Related]
8. Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator? Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N Int J Pharm; 2010 Oct; 399(1-2):31-6. PubMed ID: 20678563 [TBL] [Abstract][Full Text] [Related]
9. Ion-Pairing Contribution to the Liposomal Transport of Topotecan as Revealed by Mechanistic Modeling. Fugit KD; Anderson BD J Pharm Sci; 2017 Apr; 106(4):1149-1161. PubMed ID: 28007561 [TBL] [Abstract][Full Text] [Related]
10. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Dadashzadeh S; Vali AM; Rezaie M Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511 [TBL] [Abstract][Full Text] [Related]
11. Insights into accelerated liposomal release of topotecan in plasma monitored by a non-invasive fluorescence spectroscopic method. Fugit KD; Jyoti A; Upreti M; Anderson BD J Control Release; 2015 Jan; 197():10-9. PubMed ID: 25456833 [TBL] [Abstract][Full Text] [Related]
12. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release. Souza LG; Silva EJ; Martins AL; Mota MF; Braga RC; Lima EM; Valadares MC; Taveira SF; Marreto RN Eur J Pharm Biopharm; 2011 Sep; 79(1):189-96. PubMed ID: 21352915 [TBL] [Abstract][Full Text] [Related]
13. Mechanism and kinetics of the loss of poorly soluble drugs from liposomal carriers studied by a novel flow field-flow fractionation-based drug release-/transfer-assay. Hinna AH; Hupfeld S; Kuntsche J; Bauer-Brandl A; Brandl M J Control Release; 2016 Jun; 232():228-37. PubMed ID: 27112112 [TBL] [Abstract][Full Text] [Related]
14. Improved Therapeutic Efficacy of Topotecan Against A549 Lung Cancer Cells with Folate-targeted Topotecan Liposomes. Zhang J; Shi W; Xue G; Ma Q; Cui H; Zhang L Curr Drug Metab; 2020; 21(11):902-909. PubMed ID: 32851958 [TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo studies of different liposomes containing topotecan. Hao YL; Deng YJ; Chen Y; Wang XM; Zhong HJ; Suo XB Arch Pharm Res; 2005 May; 28(5):626-35. PubMed ID: 15974453 [TBL] [Abstract][Full Text] [Related]
16. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation. Liu JJ; Hong RL; Cheng WF; Hong K; Chang FH; Tseng YL Anticancer Drugs; 2002 Aug; 13(7):709-17. PubMed ID: 12187327 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Kong G; Anyarambhatla G; Petros WP; Braun RD; Colvin OM; Needham D; Dewhirst MW Cancer Res; 2000 Dec; 60(24):6950-7. PubMed ID: 11156395 [TBL] [Abstract][Full Text] [Related]
18. The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether-β-cyclodextrin and sucrose octasulfate. Yang W; Yang Z; Fu J; Guo M; Sun B; Wei W; Liu D; Liu H Biomater Sci; 2018 Dec; 7(1):419-428. PubMed ID: 30500018 [TBL] [Abstract][Full Text] [Related]
19. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes. Zucker D; Barenholz Y J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223 [TBL] [Abstract][Full Text] [Related]
20. Quantification of Unencapsulated Drug in Target Tissues Demonstrates Pharmacological Properties and Therapeutic Effects of Liposomal Topotecan (FF-10850). Kimura T; Okada K; Morohashi Y; Kato Y; Mori M; Kato H; Matsumoto T; Shimoyama S Pharm Res; 2024 Apr; 41(4):795-806. PubMed ID: 38536615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]